Sep 23, 2026 06:58AM
Sep 23, 2026 06:57AM
Sep 23, 2026 06:45AM
Sep 23, 2026 04:31AM
Sep 22, 2026 04:09PM
Sep 22, 2026 10:22AM
Sep 22, 2026 08:30AM FDA tells Compass Therapeutics to run survival trial before BLA
Sep 22, 2026 08:30AM
Aug 6, 2026 07:30AM
Jun 12, 2026 08:10AM
Jun 4, 2026 05:22AM
May 5, 2026 07:30AM
Apr 28, 2026 06:24AM
Apr 27, 2026 02:52PM Compass Therapeutics (CMPX) PT Lowered to $6 at Stifel
Apr 27, 2026 11:50AM
Apr 27, 2026 10:20AM
Apr 27, 2026 08:27AM
Apr 27, 2026 08:15AM
Apr 27, 2026 08:08AM
Apr 27, 2026 07:30AM
Apr 27, 2026 07:30AM Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Mar 5, 2026 07:30AM
Jan 14, 2026 10:39AM
Jan 5, 2026 04:31AM
Dec 22, 2025 07:06AM
Dec 3, 2025 03:16AM
May 8, 2025 08:00AM
Apr 1, 2025 07:01AM Compass Therapeutics, Inc (CMPX) Reports CTX-009 Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study
Apr 1, 2025 07:00AM
Nov 12, 2024 08:00AM
Sep 16, 2024 06:49AM
Aug 12, 2024 08:00AM
May 13, 2024 08:00AM
Apr 25, 2024 08:00AM
Apr 16, 2024 08:00AM Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Mar 21, 2024 09:00AM
Feb 28, 2024 08:00AM
Jan 5, 2024 08:03AM
Jan 5, 2024 08:00AM
Nov 9, 2023 07:30AM
Jun 22, 2023 04:07PM
Nov 9, 2022 04:10PM UPDATE: Compass Therapeutics (CMPX) PT Raised to $8 at Raymond James
Nov 9, 2022 09:00AM
Jul 18, 2022 07:05AM
May 16, 2022 08:00AM
May 9, 2022 08:00AM
Mar 21, 2022 08:02AM
Mar 21, 2022 08:00AM
Jan 20, 2022 08:37AM Compass Therapeutics (CMPX) Announces FDA Clearance of IND for Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 and Vascular Endothelial Growth Factor A
Jan 20, 2022 08:30AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All